| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_777a7d4b6d214f486f77cccc5afc193d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-96 |
| filingDate |
2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4e3711ecbae5f3552cd2a59aec4a504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a893964bb5cca567aa8fa7ac99c01d87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480fc71e50f2f995a7c0b8f93ca80365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0282401544ea986b823133604fbbacf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a42fb9021591807a70f5bf61309a45c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2b1102c2096c6bbc6445b314f4d8e68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d99b892a330c96246a0be3315be7f7a |
| publicationDate |
2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11180458-B2 |
| titleOfInvention |
Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer |
| abstract |
Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458144-B1 |
| priorityDate |
2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |